REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. (RGNX) on January 7, 2021, regarding a significant capital raising event. The Company, incorporated in Delaware and listed on the Nasdaq Global Select Market, entered into an underwriting agreement to sell common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 4,260,000 shares of common stock.
- Public Offering Price: $47.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 639,000 shares.
- Expected Net Proceeds: Approximately $187.8 million (base offering) or $216.0 million (if the option is fully exercised), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: BofA Securities, Inc., Morgan Stanley & Co. LLC, and Barclays Capital Inc.
- Expected Closing Date: January 12, 2021.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.
Material Changes
The primary material change is the execution of the underwriting agreement for a secondary offering of common stock. This transaction represents a significant increase in the Company's cash resources pending the closing of the offering.
Outlook, Risks, and Contingencies
The offering is subject to the satisfaction of customary closing conditions. The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions. The filing notes that certain underwriters and their affiliates have provided and may continue to provide investment banking and other financial services to the Company for which they receive customary fees.
Investor Verification Checklist
- Confirm the final closing date of the offering (expected January 12, 2021).
- Verify whether the underwriters exercised the 30-day option to purchase the additional 639,000 shares.
- Review the final net proceeds received by the Company after all expenses.
- Check subsequent filings for the updated share count and dilution impact on existing shareholders.
- Examine the press release (Exhibit 99.1) for management's stated use of proceeds.